A screening study of high-risk groups for liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease DOI Creative Commons
Guanqun Chao, Zhu Feng Yue,

Yang Bao

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Oct. 10, 2024

The purpose of this study was to explore the correlation between Hashimoto's thyroiditis and Metabolic dysfunction-associated fatty liver disease (MAFLD), at same time screen high-risk groups for fibrosis in MAFLD, find out related indicators. physical examination population included as subjects grouped according diagnostic criteria MAFLD. APRI > 1 or NFS 0.676 FIB-4 2.67were used assess people high risk fibrosis, logistic regression analysis identify factors associated with ROC curves are look indicators value. proportion lower MAFLD group. group had higher TSH levels, FT3 FT4 TGAB differences biochemical markers. Age, BMI, FBG, AST patients. curve showed that AUC age 0.741 (0.721-0.761), optimal stage value 57.5 years, while 0.729 (0.707-0.751), cut-off 39.5 U/L. patients.The is greater than equal U/L, indicating patients fibrosis.

Language: Английский

Current status and future trends of the global burden of MASLD DOI
Lei Miao, Giovanni Targher, Christopher D. Byrne

et al.

Trends in Endocrinology and Metabolism, Journal Year: 2024, Volume and Issue: 35(8), P. 697 - 707

Published: Feb. 29, 2024

Language: Английский

Citations

244
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis DOI Creative Commons
Harry Crane, Guy D. Eslick, Cameron Gofton

et al.

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: 30(3), P. 436 - 448

Published: April 16, 2024

Background/Aims: The global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. MAFLD diagnostic criteria allows objective diagnosis in the presence steatosis plus defined markers dysfunction, irrespective concurrent disease. We aimed determine total prevalence HCC cohorts (total-MAFLD), including with as their sole (single-MAFLD), and those where was a contributary factor (mixed-MAFLD).Methods: This systematic review meta-analysis included studies systematically ascertaining cohorts, using international expert panel ethnicity-specific BMI cut-offs. A comparison clinical tumour characteristics performed between single-MAFLD, mixed-MAFLD, non-MAFLD HCC.Results: 22 (56,565 individuals HCC) were included. Total single-MAFLD 48.7% (95% confidence interval [CI] 34.5–63.0%) 12.4% CI 8.3–17.3%), respectively. In due chronic hepatitis B, C, alcohol-related disease, mixed-MAFLD 40.0% 30.2–50.3%), 54.1% 40.4–67.6%) 64.3% 52.7–75.0%), Mixed-MAFLD had significantly higher likelihood cirrhosis lower metastatic spread compared HCC, platelet count macrovascular invasion HCC.Conclusions: common aetiology, but more so co-factor mixed-aetiology supporting use positive criteria.

Language: Английский

Citations

18
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients DOI
Maria Eva Argenziano, Mi Na Kim, Michele Montori

et al.

Hepatology International, Journal Year: 2024, Volume and Issue: 18(S2), P. 922 - 940

Published: July 16, 2024

Language: Английский

Citations

13
Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink DOI Creative Commons
Cornelius James Fernandez, Mohammed Alkhalifah,

Hafsa Afsar

et al.

Pathogens, Journal Year: 2024, Volume and Issue: 13(1), P. 68 - 68

Published: Jan. 10, 2024

Metabolic dysfunction-associated fatty liver disease (MAFLD) has now affected nearly one-third of the global population and become number one cause chronic in world because obesity pandemic. Chronic hepatitis resulting from B virus (HBV) C (HCV) remain significant challenges to health even 21st century. The co-existence MAFLD viral can markedly alter course individual diseases complicate management each these disorders. A thorough understanding pathobiological interactions between two infections is crucial for appropriately managing patients. In this comprehensive clinical review, we discuss various mechanisms hepatitis-mediated metabolic dysfunction impact on progression disease.

Language: Английский

Citations

11
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women DOI Creative Commons
Ilaria Milani,

Marianna Chinucci,

Frida Leonetti

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 855 - 855

Published: April 2, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic influenced by genetic, lifestyle, and environmental factors. While MASLD more prevalent in men, women are at increased risk after menopause, highlighting critical pathogenetic role of sex hormones. The complex interplay between estrogen deficiency, visceral fat accumulation, metabolic syndrome (MetS), inflammation accelerates progression, increases cardiovascular (CV) risk, triggers a cycle worsening adiposity, dysfunction, psychological problems, including eating disorders. Weight loss postmenopausal can significantly improve both outcomes, helping to prevent related conditions. This review examines prevalence MASLD, its comorbidities (type 2 diabetes T2D, CV, mental disorders), mechanisms, pharmacological treatment with GLP-1 receptor agonists (GLP1-RAs), focus on women. Given use GLP1-RAs obesity T2D patients, increase MetS this analyzes potential stable GLP-1–estrogen conjugate as therapeutic approach subgroup. By combining synergistic effects hormones, dual agonist has been shown food intake reward suppression, resulting greater weight improved insulin sensitivity, glucose, lipid metabolism. Therefore, we hypothesize that pharmacotherapy may provide targeted benefits than either hormone alone protecting liver, β-cells, overall health. As these only supported preclinical data, highlights need for future research evaluate confirm mechanisms efficacy clinical settings, particularly

Language: Английский

Citations

1
Obesity and harmful alcohol consumption are predictors for advanced liver disease in the disease management program for type 2 diabetes DOI Creative Commons
Maurice Stephan Michel, Michelle Doll,

Nastasia Albert

et al.

United European Gastroenterology Journal, Journal Year: 2024, Volume and Issue: 12(1), P. 11 - 21

Published: Jan. 11, 2024

Type 2 diabetes mellitus (T2DM) is a major risk factor for advanced liver disease. The aim of this prospective cohort study was to assess the prevalence and associated factors fibrosis cirrhosis in primary care centers participating disease management program (DMP) Germany.

Language: Английский

Citations

6
Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials DOI Creative Commons
Takumi Kawaguchi, Kenta Murotani,

Hiromitsu Kajiyama

et al.

Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 59(9), P. 836 - 848

Published: July 26, 2024

Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, potentially exerts pleiotropic effects on the liver. However, sufficient evidence is still lacking. We aimed to investigate of luseogliflozin hepatic steatosis, fibrosis, and cardiometabolic risk factors in diabetic patients by pooled meta-analysis.

Language: Английский

Citations

6
Body Composition in Chronic Liver Disease DOI Open Access
Hiroki Nishikawa, Soo Ki Kim, Akira Asai

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(2), P. 964 - 964

Published: Jan. 12, 2024

Body composition has recently been attracting people's attention, not only from a cosmetic standpoint but also the perspective of health and longevity. The body is classified into three components: fat, bone, lean soft tissue, it common to see an increase in fat decrease total muscle mass with aging. Aging-related loss function referred as primary sarcopenia, while sarcopenia caused by disease-specific conditions secondary sarcopenia. On other hand, liver-muscle axis attention recent years, become clear that liver skeletal muscles interact each other. In particular, patients cirrhosis are prone due protein-energy malnutrition, which characteristic pathophysiology disease, suggesting importance organ-organ network. this review, we would like outline latest findings field, focus on diseases such cirrhosis, fatty alcoholic hepatocellular carcinoma.

Language: Английский

Citations

5
Metabolic reprogramming in hepatocellular carcinoma: a bibliometric and visualized study from 2011 to 2023 DOI Creative Commons
Xia Li, Liping Zhou, Xinyi Xu

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: July 16, 2024

Metabolic reprogramming has been found to be a typical feature of tumors. Hepatocellular carcinoma (HCC), cancer with high morbidity and mortality, extensively studied for its metabolic reprogramming-related mechanisms. Our study aims identify the hotspots frontiers research in HCC provide guidance future scientific decision-making metabolism. Relevant studies on were derived from Web Science Core Collection (WoSCC) database up until November 2023. The bibliometrix tools R used scientometric analysis visualization. From 2011 2023, total 575 publications obtained WoSCC that met established criteria. These involved 3,904 researchers 948 organizations 37 countries, an average annual growth rate 39.11% research. published 233 journals, Cancers (n = 29) ranking first, followed by Frontiers Oncology 20) International Journal Molecular Sciences 19). top ten journals accounted 26% studies. most prolific authors Wang J 14), Li Y 12), Liu 12). country is China, United States, Italy, France. Fudan University had largest percentage results 15.48% 89). Ally A's paper Cell citations. A 1,204 keywords analyzed, trend themes such as "glycolysis," "tumor microenvironment," "Warburg effect," "mitochondria," "hypoxia ," etc. Co-occurrence network cluster revealed relationships between keywords, authors, publications, journals. Moreover, close collaboration countries this field was elucidated. This bibliometric visual delves into related 2012 elucidating characteristics field, which gradually moved away single glycolipid metabolism integration overall body, pointing out topics, dynamics interaction tumor microenvironment will direction research, provides blueprints inspirations prevention treatment programs field. Systematic Review Registration: [https://www.bibliometrix.org].

Language: Английский

Citations

4
Metabolic dysfunction associated fatty liver disease in healthy weight individuals DOI Creative Commons
Nahúm Méndez‐Sánchez, Willem Pieter Brouwer, Frank Lammert

et al.

Hepatology International, Journal Year: 2024, Volume and Issue: 18(S2), P. 884 - 896

Published: July 25, 2024

Metabolic dysfunction associated fatty liver disease (MAFLD) is an increasing public health problem, affecting one third of the global population. Contrary to conventional wisdom, MAFLD not exclusive obese or overweight individuals. Epidemiological studies have revealed a remarkable prevalence among healthy weight individuals, leading investigations into genetic, lifestyle, and dietary factors that contribute development in this This shift perspective requires reconsideration preventive strategies, diagnostic criteria therapeutic approaches tailored address unique characteristics It also underscores importance widespread awareness education, within medical community general population, promote more inclusive understanding metabolic disorders. With review, we aim provide comprehensive exploration encompassing epidemiological, pathophysiological, clinical aspects.

Language: Английский

Citations

4